Searchable abstracts of presentations at key conferences in endocrinology

ea0073aep160 | Diabetes, Obesity, Metabolism and Nutrition | ECE2021

Could we use SGLT2 inhibitors without serious concern in the elderly?

Ihintza Larrañaga , Vives Cristina Goena , Maria Magdalena Arteaga Ossa , Alvaro Jorge Rojo , Laura Mañas Alonso , Ovejero Laura Quintas , Begoña Maíz Alcorta , Rodrigo Ana Moreno , Nerea Andrés Imaz , Irene Larrañaga Gomez , Villar Ruth Agirrezabalaga , Abasolo Amaia Aspiazu , Suarez Teresa Arana , Dadebat Naroa Rico , Amaia Cristina Armentia Del Pozo , Irizar Sara Diez , Tijero Naroa Gomez , Jose Francisco Egido Arroyo

BackgroundTherapeutic experience with SGLT2i is limited in the elderly. Its initiation is not recommended in patients over 85 years based on volume depletion risk. The aim of this study is to analyze clinical efficacy and safety of SGLT2i in elder T2DM patients.MethodsThis observational retrospective study included 544 T2DM subjects who initiated SGLT2i as add-on treatment between February 2018–2019 and ...